Cranberry-derived OTC UTI treatment found to be as effective as Rx antibiotic
KEARNY, N.J. A recent study published in the Journal of Antimicrobial Chemotherapy, a peer-reviewed publication, has found that the administration of Cran-Max was comparable to the commonly prescribed antibiotic, trimethoprim, for the prevention of recurrent urinary tract infections in older women.
“Our trial is the first to evaluate cranberry (Cran-Max) in the prevention of recurrent UTIs specifically in older women, and the first head-to-head double-blind comparison of cranberry versus antibiotic prophylaxis,” stated )Proprietary Nutritionals, which markets Cran-Max. “Trimethoprim had a very limited advantage over cranberry extract (Cran-Max) in the prevention of recurrent UTIs in older women and had more adverse effects.”
“This is a landmark study for Cran-Max and the nutritional supplement industry demonstrating the benefits of a natural product for prevention,” stated Sherry Torkos, author of The Benefits of Berries. “Prevention of UTI with antibiotics is effective but undesirable due to side effects, most commonly diarrhea, upset stomach and yeast infection.”
“Antimicrobial resistance is another concern,” said Torkos. “In fact, resistance to trimethoprim in bacteria causing UTIs has been steadily increasing in Northern European and American countries from as high as 15 percent in the 1970s to about 24 percent in 2004.”
“This study comes on the heels of another landmark study sponsored by a European government agency that commenced in 2005 on 560 women which will be completed this month,” stated Dean Mosca, president of Proprietary Nutritionals. “It compares Cran-Max to a 480 mg dose of trimethoprim-sulfamethoxazole for a one-year period. A comprehensive body of science is developing for Cran-Max as an efficacious, recommended UTI preventative by medical professionals,” he said.
Urinary tract infections are the most common infection in older adults, and the second most common infection in women.
GSI Commerce, GNC agree to extend e-commerce partnership
PITTSBURGH, Pa. GSI Commerce and GNC on Tuesday announced a multiyear extension and expansion of the e-commerce agreement between the two companies. Under the agreement, which runs through 2017, GSI will continue to provide GNC’s online store with e-commerce technology, order management and customer care operations.
“Since partnering with GSI, our online business has become an important channel for both product sales and information,” said Beth Kaplan, president and chief merchandising and marketing officer for GNC. “We are excited about extending our e-commerce agreement with GSI and expanding our relationship to include interactive marketing services.”
In addition to e-commerce services, the agreement names GSI’s digital agency, gsi interactive, as GNC’s digital agency of record and adds a full complement of marketing services that include site usability testing, paid search marketing, comparison shopping engines, affiliate marketing, display advertising, emerging media, and e-mail services powered by e-Dialog, GSI’s e-mail marketing subsidiary.
“We are very happy that GNC will continue to build its online business with GSI as its e-commerce partner,” said Scott Hardy, executive vice president of business management for GSI. “This long-term, multiyear, and expanded agreement speaks to the success of the relationship and to the opportunity in front of us for continued growth.”
GNC launched its online store on GSI’s e-commerce platform in the fourth quarter of 2005. Online sales have since become an important channel for GNC as well as a valuable extension of its brand, the company stated.
Forbes names Home Diagnostics one of its 200 best small businesses
FORT LAUDERDALE, Fla. Home Diagnostics on Tuesday announced that it was named one of Forbes magazine’s “200 Best Small Companies” in the October 27 issue of that publication, which makes for HDI’s debut on the Forbes list.
“Being recognized by Forbes as one of the nation’s best small companies is a testament to the success of Home Diagnostics’ growth strategy,” stated Richard Damron, Jr., president and chief executive officer of Home Diagnostics. “National pharmacy chains, distributors and mail service providers trust our blood glucose monitoring systems to represent their own brands because we offer high-performance products at a significant cost savings to their diabetic customers. Our ability to capitalize on our unique distribution model and gain market share with competitive price points positions Home Diagnostics as a strong player in a growing $7 billion diabetes testing supplies market.”
“The Forbes list of the 200 Best Small Companies seeks to identify the strongest public companies with sales under $750 million,” said Kurt Badenhausen associate editor at Forbes. “These firms all have reasonable debt burdens and have had solid sales and earnings growth over the past five years.”